GSE199107 tryptophan 3 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE199107_tryptophan_3_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE199107_tryptophan_3_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE199107_tryptophan_3_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE199107_tryptophan_3_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

valyl-tRNA synthetase 1

Gene

H3.3 histone A

Gene

differentiation antagonizing non-protein coding RNA

Gene

CASTOR family member 3, pseudogene

Gene

long intergenic non-protein coding RNA 511

Gene

FGD5 antisense RNA 1

Gene

long intergenic non-protein coding RNA 2593

Gene

long intergenic non-protein coding RNA 3219

Gene

ribosomal protein S2 pseudogene 5

Gene

long intergenic non-protein coding RNA 1106

  • Gene

    valyl-tRNA synthetase 1



  • Gene

    differentiation antagonizing non-protein coding RNA


  • Gene

    CASTOR family member 3, pseudogene


  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    FGD5 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 2593


  • Gene

    long intergenic non-protein coding RNA 3219


  • Gene

    ribosomal protein S2 pseudogene 5


  • Gene

    long intergenic non-protein coding RNA 1106

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.